Skip to Content
Stock Analyst Update

Johnson & Johnson Posts Steady 2nd-Quarter Results

We don't expect any major changes to our fair value estimate after results were in line with expectations.


 Johnson & Johnson (JNJ) reported second-quarter results largely in line with both our expectations and those of consensus, and we don't expect any major changes to our fair value estimate. We continue to view the stock as largely fairly valued, as the investment community appreciates the company's strengths and weaknesses. The quarter's steady results reaffirm our wide moat rating.

Led once again by strong drug sales, total sales increased operationally 6% year over year. The drug group's 11% growth was slightly higher than we expected, driven by robust immunology and oncology drug sales. However, we expect the growth in these therapeutic areas will moderate. We expect further price declines from immunology drug Remicade due to biosimilar pressures that we estimate have caused Remicade's price to decline by close to 15% already. We also expect growth for immunology drug Stelara to stagnate as share gains in the Crohn's indication (led by strong clinical data) are offset by share losses in psoriasis due to increased competition from IL17 drugs. In oncology, increasing generic competition to Zytiga (expected in the fourth quarter, ahead of management guidance) and Velcade (expected in 2019) should pressure the company's overall cancer drug sales. Outside of drugs, the more modest growth of 1% in consumer and 3% in devices was largely expected as competitive pressures have weighed on growth, and we expect this trend will continue through 2019.

Earnings-per-share increased 18.5% as the strong sales gains in the higher margin drug group helped amplify growth on the bottom line. We expect this trend will continue as Johnson & Johnson's drug unit is best positioned for growth over the next three years. Additionally, while it faces potentially heavy legal charges against the firm's Talcum powder potentially causing cancer, we expect Johnson & Johnson will litigate the cases aggressively and the final related payments will not cause a major impact to its valuation.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.